Search clinical trials for: Placebo for Aliskiren

Total 69681 results

Novartis

Completed

A Study to Evaluate the Safety/Tolerability and Pharmacokinetics of Aliskiren in Hypertensive Pediatric and Adolescent Patients 6-17 Years of Age

Hypertension

Hungary, Poland, United States, Belgium, Brazil
Novartis Pharmaceuticals

Completed

Study to Evaluate the Efficacy and Safety of Aliskiren Alone and in Combination With Amlodipine in Essential Hypertension

Hypertension

Sweden, United States, Peru, Russian Federation, Romania, Mexico, Panama, Spain, Denmark, Italy, Greece, South Africa, Canada, Argentina, Australia, Colombia, Finland, Taiwan
Jichi Medical University

Completed

Effects of Aliskiren in Elderly Hypertensive Chronic Kidney Disease (CKD) Patients

Hypertension | Chronic Kidney Disease

Japan
Novartis

Completed

Efficacy of Aliskiren Compared to Ramipril in the Treatment of Moderate Systolic Hypertensive Patients (ALIAS)

Essential Hypertension

France
John H. Stroger Hospital

Terminated

Triple Blockade of the Renin Angiotensin Aldosterone System in Diabetic (Type 1&2) Proteinuric Patients

Diabetes | Proteinuria | Albuminuria | Microalbuminuria | Macroalbuminuric Diabetic Nephropathy

United States
Novartis Pharmaceuticals

Completed

Effects of Aliskiren, Ramipril, and the Combination on Levels of Angiotensin II in Patients With Decompensated Systolic Heart Failure (ESCAPE-SHF)

Heart Failure

Russian Federation, Germany, Poland
Materia Medica Holding

Completed

Clinical Trial of Efficacy and Safety of Anaferon for Children Liquid Dosage Form in the Treatment of Acute Upper Respiratory Infections

Acute Upper Respiratory Infections

Russian Federation
Novartis

Completed

A Clinical Study to Evaluate the Safety and Efficacy of Aliskiren Alone and in Combination With Ramipril in Hypertensive, Diabetic Patients.

Hypertension, Diabetes Mellitus

United States, Germany
Novartis

Completed

Efficacy and Safety of Aliskiren 300mg Compared to Irbesartan 300mg and Ramipril 10 mg in the Setting of a Missed Dose for Patients With Essential Hypertension.

Essential Hypertension

Switzerland, Germany
Merck Sharp & Dohme LLC

Completed

The Effect of Hypertension Medications on Renal Blood Flow Measurements in Healthy Males (MK-0000-127)

Hypertension
Chulalongkorn University

Unknown

The Effect of Aliskiren and Losartan on Peritoneal Membrane in Continuous Ambulatory Peritoneal Dialysis Patients

Peritoneal Membrane Failure

Thailand
Novartis Pharmaceuticals

Completed

Comparison of Aliskiren and Amlodipine on Insulin Resistance and Endothelial Dysfunction in Patients With Hypertension and Metabolic Syndrome

Metabolic Syndrome | Insulin Resistance | Endothelial Dysfunction | High Blood Pressure

United States
Novartis

Completed

Clinical Study to Evaluate Efficacy and Safety of Aliskiren (150mg & 300mg) Administered Alone and in Combo With Valsartan (160mg and 320mg) in Patients With High Blood Pressure

Hypertension

United States, Germany
Kagawa University

Unknown

A Prospective Study of the Kidney Protective Effect of Aliskiren in Hypertensive Patients With IgA Nephropathy

Hypertension | Glomerulonephritis, IGA

Japan
Novartis

Completed

A Clinical Study to Evaluate the Safety and Efficacy of the Combination of Aliskiren and Valsartan in Hypertensive Non Responders Patients

Hypertension

United States, Germany
Novartis

Completed

Effects of Aliskiren, Irbesartan, and the Combination in Hypertensive Patients With Type 2 Diabetes and Diabetic Nephropathy

Diabetes Type 2

Denmark
Novartis Pharmaceuticals

Completed

Aliskiren in Combination With Losartan Compared to Losartan on the Regression of Left Ventricular Hypertrophy in Overweight Patients With Essential Hypertension (ALLAY)

Hypertension | Overweight | Left Ventricular Hypertrophy

United States, Finland, Sweden, Germany, Italy, Spain, Argentina, Colombia, Russian Federation
Novartis

Completed

Clinical Study to Evaluate the Efficacy and Safety of Aliskiren Alone and in Combination With Hydrochlorothiazide in Patients With Essential Hypertension.

Hypertension

Germany, United States
Novartis

Terminated

Effects of Aliskiren and Amlodipine on the Renin-Angiotensin System (RAS) and Lipid/Carbohydrate Metabolism in Obese Patients With Hypertension

Hypertension | Abdominal Obesity

Germany
Novartis
The TIMI Study Group

Completed

Efficacy and Safety of Aliskiren and Valsartan Versus Placebo in Patients Stabilized Following an Acute Coronary Syndrome

Myocardial Ischemia | Post Acute Coronary Syndrome

Germany, Spain, United States, Belgium, Canada, Czech Republic, Hungary, Netherlands, Poland, Russian Federation, Sweden
Novartis

Completed

A Clinical Study to Evaluate Safety & Efficacy of the Combination of Aliskiren, Valsartan & Hydrochlorothiazide in Diabetic Hypertensive Nonresponder Patients

Hypertension | Diabetes

Switzerland, Sweden, Romania, Belgium, Spain, United States, Ukraine
Novartis

Completed

A Clinical Study to Compare an Aliskiren Based Hypertensive Regimen With a Ramipril Based One Followed by a Randomized Withdrawal.

Hypertension

United States
Novartis

Completed

A Clinical Study to Evaluate the Long-term Safety (12 Months) of the Combination of Aliskiren 300 mg and Hydrochlorothiazide 25 mg

Hypertension

United States, Belgium, Canada, Germany, Italy, Netherlands, Peru, Russian Federation, Switzerland, United Kingdom
Novartis

Completed

A Clinical Study to Assess Efficacy and Safety of Aliskiren in the Elderly With High Blood Pressure

Hypertension

Switzerland
Novartis

Completed

Long Term Safety of Aliskiren Alone or With the Optional Addition of Hydrochlorothiazide in Patients With Essential Hypertension

Hypertension

Germany
Novartis

Completed

A Clinical Study to Compare the Safety and Efficacy of an Aliskiren-based Regimen With a Lisinopril Based Regimen in Patients With Severe Hypertension

Hypertension

Switzerland, Spain, Hungary, Germany
Novartis

Completed

A Safety and Efficacy Trial of the Combination of Aliskiren / Hydrochlorothiazide (HCTZ)(300/12.5 mg and 300/25 mg) Compared to Aliskiren 300 mg in Hypertensive Patients

Hypertension

United States, Germany
Novartis

Completed

Safety/Efficacy of Combo Therapy With Aliskiren & Hydrochlorothiazide vs Therapy With Hydrochlorothiazide Alone in Patients With Hypertension

Hypertension

United States, Germany
Novartis

Completed

Study Comparing SPP100 (Aliskiren) 150mg to Placebo and to Losartan 50mg in Patients With Mild to Moderate Essential Hypertension

Hypertension

Japan
Novartis

Completed

Efficacy and Safety of Aliskiren and Atenolol in Adults (>18) With Mild to Moderate Hypertension

Hypertension

Germany, Switzerland
Novartis Pharmaceuticals

Terminated

Assessment of Aliskiren/Amlodipine and Amlodipine on Ankle Foot Volume (AFV) in Patients With Hypertension

Hypertension | Ankle Edema

Netherlands
Sir Mortimer B. Davis - Jewish General Hospital
Novartis Pharmaceuticals

Withdrawn

Aliskiren vs Hydrochlorothiazide in Hypertensive Type II Diabetic Patients on Resistance Arteries

Hypertension | Diabetes

Canada
EnnovaBio Australia Pharmaceuticals Pty Ltd

Not yet recruiting

A First-in-Human SAD/MAD Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ENC1018 in Healthy Adult Subjects

Healthy
Novartis Pharmaceuticals

Completed

Safety and Efficacy of Aliskiren When Added to Standardized Losartan and Optimal Antihypertensive Therapy in Patients With Hypertension, Type 2 Diabetes and Proteinuria

Diabetic Nephropathy

United States, Germany, Netherlands, Russian Federation, United Kingdom, Romania, Spain, France, Italy, Greece, Canada, Denmark
ZYUS Life Sciences Inc.
Novotech (Australia) Pty Limited; ZYUS Life Sciences Australia Pty Ltd

Completed

Trichomylin® Safety, Tolerability & Pharmacokinetics in Healthy Adults and First in Human Osteoarthritis Pain Evaluation (HOPE)

Healthy | Osteoarthritis

Australia
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of IBI356 in Healthy Participants and in Atopic Dermatitis Patients

Healthy Participants | Atopic Dermatitis Patients

China
Novartis Pharmaceuticals

Terminated

To Study the Effects of Aliskiren on Albuminuria and Various Biomarkers in Patients With Nephropathy (ARIA)

Non-diabetic Nephropathy

Netherlands
Theravance Biopharma

Completed

SAD and MAD Study to Evaluate Safety, Tolerability, and Pharmacokinetics (PK) of TD-1473 in Healthy Subjects

Healthy

United States
The University of Hong Kong
Queen Mary Hospital, Hong Kong; United Christian Hospital

Completed

Aliskiren for Proteinuric IgAN Despite Angiotensin Blockade

IgA Nephropathy

China
Novartis

Completed

A Clinical Study to Compare Long-term Efficacy and Safety of an Aliskiren Based Regimen to a Hydrochlorothiazidebased Treatment Regimen With Optional Addition of Amlodipine

Hypertension

Switzerland, Germany
UMC Utrecht

Unknown

Aliskiren and Muscle Sympathetic Nerve Activity (MSNA)

Hypertension | Chronic Kidney Disease | Muscle Sympathetic Nerve Activity

Netherlands
Lerdsin General Hospital

Unknown

Safety of Add on Aliskiren to Angiotensin Converting Enzyme Inhibitor (ACEI) and Angiotensin I Receptor Blocker (ARB) Treatment in Type 2 Diabetes With Nephropathy

Type 2 Diabetes With Nephropathy

Thailand
Chong Kun Dang Pharmaceutical

Recruiting

A Clinical Trial to Evaluate the Efficacy and Safety of CKD-391 and CKD-331 in Patients With Primary Hypercholesterolemia

Primary Hypercholesterolemia

Korea, Republic of
Novartis

Completed

A Clinical Study to Evaluate the Safety and Efficacy of the Combination of Aliskiren and Amlodipine in Hypertensive Non Responders Patients

Hypertension

Germany, United States
Novartis

Completed

A Clinical Study With Aliskiren Alone or in Combination Therapy With Diuretic Hctz in Venezuelan Hypertensive Patients. (ANDROMEDA)

High Blood Pressure

Venezuela
Spero Therapeutics
Simbec Research

Completed

A Study of the Safety, Tolerability, and Pharmacokinetics of SPR720 in Healthy Volunteers

Healthy Volunteers

United Kingdom
Hanmi Pharmaceutical Company Limited

Completed

Trial to Evaluate the Efficacy and Safety of HCP1302

Hypertension | Erectile Dysfunction
Eli Lilly and Company
OPKO Health, Inc.

Completed

A Study to Test the Combination of Two Different Kinds of Medications for the Treatment of Diabetes

Diabetes Mellitus, Type 2

United States, Puerto Rico
AstraZeneca

Completed

A Study of MEDI7352 in Painful Osteoarthritis of the Knee

Chronic Pain

Germany, Sweden, United Kingdom
Meir Medical Center
Novartis Pharmaceuticals

Terminated

Evaluation of Aliskiren Efficacy by Different Methods of Blood Pressure Measurements (REALITY)

Blood Pressure, High

Israel

3

Subscribe